CN105777799B - A kind of benzoyl hydrazone Dibenzyltin complex and its preparation method and application - Google Patents
A kind of benzoyl hydrazone Dibenzyltin complex and its preparation method and application Download PDFInfo
- Publication number
- CN105777799B CN105777799B CN201610254542.0A CN201610254542A CN105777799B CN 105777799 B CN105777799 B CN 105777799B CN 201610254542 A CN201610254542 A CN 201610254542A CN 105777799 B CN105777799 B CN 105777799B
- Authority
- CN
- China
- Prior art keywords
- complex
- benzoyl hydrazone
- hydrazone dibenzyltin
- carbonyl
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/22—Tin compounds
- C07F7/2284—Compounds with one or more Sn-N linkages
Abstract
The invention discloses a kind of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complexs, are the complex of following structure formula (I), wherein Ph is phenyl, and R is benzyl.The invention also discloses the preparation method of the 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex and preparing the application in anticancer drug.
Description
Technical field
The present invention relates to a kind of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex and preparation method thereof, with
And the 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex is preparing the application in anticancer drug.
Background technique
Organotin is a kind of metallo-organic compound containing Sn-C key.Researcher just notices before very early
The Anticancer Activity in vitro of organo-tin compound.1972, Brown had found Ph for the first time3SnOOCCH3To the growth tool of mouse cancer cell
There is inhibiting effect.1980, Crowe etc. chemists' studies have shown that many organo-tin compounds have anti tumor activity in vitro.
1989, American National anticancer research institute（National Cancer Institute）To more than 2,000 kinds of organo-tin compounds into
Antitumor activity screening is gone, the results showed that some organo-tin compounds have inhibiting effect to P388 lymphocytic leukemia.
2002, Gielen et al. did comprehensive summing up in the activity to organotin carboxylate's ester compounds, thought many organic after research
Tin compound has preferable Anticancer Activity in vitro really.
Studies have shown that the organic group connected on organic tin atom and the ligand for participating in being coordinated decide organo-tin compound
Bioactivity, select it is some itself with the active organic ligand of good biological in organotin tin atoms be coordinated causes
The great interest of people.Acylhydrazone is one kind Schiff alkali cpd made of being modified as hydrazide kind compound, it
Be condensed by aldehydes or ketones and hydrazides, with good bioactivity, stronger coordination ability and multiplicity coordination mode, and
And medicine, pesticide, material and in terms of have a wide range of applications.In recent years, domestic and international many researchers couple
It compares in terms of bioactivity and in depth studies, and research finds that acylhydrazone has anticancer, sterilization, anti-inflammatory etc.
Various active.Therefore, by acylhydrazone class Schiff aar ligand in conjunction with organotin, it is intended to obtain the stronger new chemical combination of bioactivity
Object becomes the interested research direction of people.
Chinese patent CN 102718794A disclose a kind of double acylhydrazone class Schiff alkali stannous phenide complexs and its
Prepare Antilung gland cancer, colon cancer, leukaemia cell drug in application.
Chinese patent CN 101851251A disclose a kind of acylhydrazone class Schiff aar ligand dibutyl tin complex and
Its application in the drug of preparation treatment liver cancer, adenocarcinoma of lung, breast cancer, prostate cancer, colon cancer or early young grain leukaemia.
Document（Journal of Organometallic Chemistry, 2014,75: 83-91）Report, organotin
Acylhydrazone class Schiff alkali complex is to human colon cancer cell（HCT-116）, human lung adenocarcinoma cell（A549）, human umblilical vein endothelial
Cell（HUVEC）With compared with strong biological activity, and it is better than carboplatin.
Document（Journal of Organometallic Chemistry, 2013,724: 23-31）Report, series have
Machine tin acylhydrazone class Schiff alkali complex, organo-tin compound and acylhydrazone class Schiff aar ligand are respectively to human lung adenocarcinoma
Cell（A549）, human colon cancer cell（HCT-8）, people in loop（hl-60）The inhibiting effect of equal cancer cells.
Document（Bioorganic & Medicinal Chemistry Letters, 2015, 25: 4461- 4463）
Report, a variety of acylhydrazone class Schiff aar ligands are to human liver cancer cell（HuH-7）And human lung adenocarcinoma cell（A549）Anticancer it is living
Property.
It is the experiment proved that the substance with anticancer activity, the present invention based on acylhydrazone class Schiff alkali organotin complex
Selection benzoyl hydrazine, Sodium.beta.-phenylpyruvate react under certain condition with TriphenylphosphineoxComplex, and synthesis has been obtained to human colon carcinoma
Cell（Colo205）, human liver cancer cell（HepG2）, breast cancer cell（MCF7）, cervical cancer cell（Hela）It is thin with human lung cancer
Born of the same parents（NCI-H460）Complex with certain inhibitory activity provides new approach for exploitation anticancer drug.
Summary of the invention
There is provided a kind of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complexs for the first object of the present invention.
The second object of the present invention is to provide above-mentioned 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex preparation
Method.
The third object of the present invention is to provide above-mentioned 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex and is making
Application in standby anticancer drug.
A kind of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex as the first aspect of the present invention is
The complex of structure formula (I)
(I)
Wherein Ph is phenyl, and R is benzyl.
2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex of the invention is through elemental analysis, infrared spectroscopy, core
Magnetic resonance spectrum and X-ray single crystal diffraction structural analysis, it is as a result as follows：
Elemental analysis (C62H60N4O8Sn2)：Calculated value：C 60.71, H 4.93, N 4.57；Measured value：C 60.74, H
4.99, N 4.59.
FT-IR (KBr, ν/cm-1): 3080, 3059, 3024, 2930, 1630, 1614, 1597, 1391,
1338, 696, 590, 555, 455, 440。
1H NMR (400 MHz, DMSO-d 6) δ(ppm): 7.87 (d, J = 7.1 Hz, 2H), 7.51-7.41
(m, 3H), 7.21-7.13 (m, 3H), 6.96 (d, J = 6.8 Hz, 2H), 6.78 (s, 6H), 6.69(m,
4H), 4.04 (s, 1H), 3.47 (s, 3H), 3.17 (s, 2H,), 2.88-2.81 (m, 4H)。
13C NMR (100 MHz, DMSO-d 6) δ(ppm): 172.75, 164.04, 151.85, 138.30,
135.97, 134.47, 130.72, 128.86, 127.90, 127.80, 127.76, 127.68, 127.10,
125.59, 123.79, 48.38, 37.04, 31.33。
119Sn NMR (187 MHz, DMSO-d 6) δ(ppm): -453.90。
2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex of the invention is crystal structure, crystal three
Oblique system, space group P-1, a=0.95601 (4) nm, b=1.22653 (5) nm, c=1.26730 (5) nm, α=
78.19 °, β=71.78 °, γ=86.0410 (10) °, Z=2, V=1.38155 (10) nm3, the Mgm of Dc=1.474-3, m
(MoKα)= 0.963 mm-1, F (000)=624.
2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex of the invention is structurally characterized in that：Tin in molecule
Atom is seven coordination distortion pentagonal bipyramid configurations.
2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex of the invention has certain thermostabilization range,
It can be stabilized at 103 DEG C or less.
A kind of system of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex as a second aspect of the invention
Preparation Method, be added in the reaction vessel for having nitrogen protection TriphenylphosphineoxComplex, benzoyl hydrazine, Sodium.beta.-phenylpyruvate and solvent without
Water methanol reacts 5 ~ 24 h under conditions of temperature is 45 ~ 65 DEG C, cooling, and filtering controls solvent under conditions of 20 ~ 35 DEG C
Volatilization crystallization, obtains colourless transparent crystal, as 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex.
In a preferred embodiment of the invention, the TriphenylphosphineoxComplex, benzoyl hydrazine, Sodium.beta.-phenylpyruvate three
The mass ratio of the material be 1:(1~1.05):(1.05~1.15).
In a preferred embodiment of the invention, the solvent anhydrous methanol dosage is every mM of dibenzyl dichloride
Tin adds 15 ~ 35 milliliters.
A kind of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex as the third aspect of the present invention is being made
Application in standby anticancer drug.
It is living that applicant has carried out extracorporeal anti-tumor to above-mentioned 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex
Property determine research, it is thus identified that 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex has certain Anti-cancer biologic living
Property, that is to say, that the purposes of above-mentioned complex is to prepare the application in anticancer drug, is specifically exactly to prepare anti-human knot
Intestinal cancer, human liver cancer, human breast carcinoma, human cervical carcinoma, the application in human lung cancer drug.
2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex of the invention is to human colon cancer cell, human liver cancer
Cell, human breast cancer cell, human cervical carcinoma cell, human lung carcinoma cell etc. show good anticancer activity, 2- of the invention
The features such as carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex anticancer activity is high, at low cost, preparation method is simple be
It develops new anticancer drug and provides new way.
Detailed description of the invention
Fig. 1 is the IR spectrogram of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex.
Fig. 2 is 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex1H NMR spectra.
Fig. 3 is 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex13C NMR spectra.
Fig. 4 is 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex119Sn NMR spectra.
Fig. 5 is the crystal structure figure of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex.
Fig. 6 is the TG-DTG curve of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex.
Specific embodiment
By following embodiment, present invention be described in more detail, but should be noted that the scope of the present invention is not implemented by these
Any restrictions of example.
Embodiment 1：
The preparation of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex：
In the 100mL three-necked flask for having nitrogen protection be added 0.372g (1.0mmol) TriphenylphosphineoxComplex,
0.136g (1.0mmol) benzoyl hydrazine, 0.205g (1.1mmol) Sodium.beta.-phenylpyruvate and 25mL solvent anhydrous methanol, in temperature
8 h are reacted under conditions of being 45 ~ 65 DEG C, cooling, filtering controls solvent volatilization crystallization under conditions of 20 ~ 35 DEG C, obtains colourless
Bright crystal, as 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex.Yield：74.4%.Fusing point：103~105℃
(dec)。
Elemental analysis (C62H60N4O8Sn2)：Calculated value：C 60.71, H 4.93, N 4.57；Measured value：C 60.74, H
4.99, N 4.59.
FT-IR (KBr, ν/cm-1): 3080, 3059, 3024, 2930, 1630, 1614, 1597, 1391,
1338, 696, 590, 555, 455, 440。
1H NMR (400 MHz, DMSO-d 6) δ(ppm): 7.87 (d, J = 7.1 Hz, 2H), 7.51-7.41
(m, 3H), 7.21-7.13 (m, 3H), 6.96 (d, J = 6.8 Hz, 2H), 6.78 (s, 6H), 6.69(m,
4H), 4.04 (s, 1H), 3.47 (s, 3H), 3.17 (s, 2H,), 2.88-2.81 (m, 4H)。
13C NMR (100 MHz, DMSO-d 6) δ(ppm): 172.75, 164.04, 151.85, 138.30,
135.97, 134.47, 130.72, 128.86, 127.90, 127.80, 127.76, 127.68, 127.10,
125.59, 123.79, 48.38, 37.04, 31.33。
119Sn NMR (187 MHz, DMSO-d 6) δ(ppm): -453.90。
Crystallographic data：Anorthic system, space group P-1, a=0.95601 (4) nm, b=1.22653 (5) nm, c=
1.26730 (5) nm, α=78.19 °, β=71.78 °, γ=86.0410 (10) °, Z=2, V=1.38155 (10) nm3,
Dc= 1.474 Mg·m-3, m (MoK α)=0.963 mm-1, F (000)=624.
Embodiment 2：
The preparation of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex：
In the 100mL three-necked flask for having nitrogen protection be added 0.372g (1.0mmol) TriphenylphosphineoxComplex,
0.136g (1.0mmol) benzoyl hydrazine, 0.195g (1.05mmol) Sodium.beta.-phenylpyruvate and 35mL solvent anhydrous methanol, in temperature
5 h are reacted under conditions of being 45 ~ 65 DEG C, cooling, filtering controls solvent volatilization crystallization under conditions of 20 ~ 35 DEG C, obtains colourless
Bright crystal, as 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex.Yield：77.0%.Fusing point：103~105℃
(dec)。
Elemental analysis (C62H60N4O8Sn2)：Calculated value：C 60.71, H 4.93, N 4.57；Measured value：C 60.74, H
4.99, N 4.59.
FT-IR (KBr, ν/cm-1): 3080, 3059, 3024, 2930, 1630, 1614, 1597, 1391,
1338, 696, 590, 555, 455, 440。
1H NMR (400 MHz, DMSO-d 6) δ(ppm): 7.87 (d, J = 7.1 Hz, 2H), 7.51-7.41
(m, 3H), 7.21-7.13 (m, 3H), 6.96 (d, J = 6.8 Hz, 2H), 6.78 (s, 6H), 6.69(m,
4H), 4.04 (s, 1H), 3.47 (s, 3H), 3.17 (s, 2H,), 2.88-2.81 (m, 4H)。
13C NMR (100 MHz, DMSO-d 6) δ(ppm): 172.75, 164.04, 151.85, 138.30,
135.97, 134.47, 130.72, 128.86, 127.90, 127.80, 127.76, 127.68, 127.10,
125.59, 123.79, 48.38, 37.04, 31.33。
119Sn NMR (187 MHz, DMSO-d 6) δ(ppm): -453.90。
Crystallographic data：Anorthic system, space group P-1, a=0.95601 (4) nm, b=1.22653 (5) nm, c=
1.26730 (5) nm, α=78.19 °, β=71.78 °, γ=86.0410 (10) °, Z=2, V=1.38155 (10) nm3,
Dc= 1.474 Mg·m-3, m (MoK α)=0.963 mm-1, F (000)=624.
Embodiment 3：
The preparation of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex：
In the 100mL three-necked flask for having nitrogen protection be added 0.372g (1.0mmol) TriphenylphosphineoxComplex,
0.142g (1.05mmol) benzoyl hydrazine, 0.214g (1.15mmol) Sodium.beta.-phenylpyruvate and 30mL solvent anhydrous methanol, in temperature
Degree reacts 15 h under conditions of being 45 ~ 65 DEG C, cooling, filtering, and solvent volatilization crystallization is controlled under conditions of 20 ~ 35 DEG C, obtains nothing
Color transparent crystal, as 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex.Yield：78.2%.Fusing point：103~
105℃(dec)。
Elemental analysis (C62H60N4O8Sn2)：Calculated value：C 60.71, H 4.93, N 4.57；Measured value：C 60.74, H
4.99, N 4.59.
FT-IR (KBr, ν/cm-1): 3080, 3059, 3024, 2930, 1630, 1614, 1597, 1391,
1338, 696, 590, 555, 455, 440。
1H NMR (400 MHz, DMSO-d 6) δ(ppm): 7.87 (d, J = 7.1 Hz, 2H), 7.51-7.41
(m, 3H), 7.21-7.13 (m, 3H), 6.96 (d, J = 6.8 Hz, 2H), 6.78 (s, 6H), 6.69(m,
4H), 4.04 (s, 1H), 3.47 (s, 3H), 3.17 (s, 2H,), 2.88-2.81 (m, 4H)。
13C NMR (100 MHz, DMSO-d 6) δ(ppm): 172.75, 164.04, 151.85, 138.30,
135.97, 134.47, 130.72, 128.86, 127.90, 127.80, 127.76, 127.68, 127.10,
125.59, 123.79, 48.38, 37.04, 31.33。
119Sn NMR (187 MHz, DMSO-d 6) δ(ppm): -453.90。
Crystallographic data：Anorthic system, space group P-1, a=0.95601 (4) nm, b=1.22653 (5) nm, c=
1.26730 (5) nm, α=78.19 °, β=71.78 °, γ=86.0410 (10) °, Z=2, V=1.38155 (10) nm3,
Dc= 1.474 Mg·m-3, m (MoK α)=0.963 mm-1, F (000)=624.
Embodiment 4：
The preparation of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex：
In the 250mL three-necked flask for having nitrogen protection be added 1.860g (5.0mmol) TriphenylphosphineoxComplex,
0.694g (5.1mmol) benzoyl hydrazine, 1.004g (5.4mmol) Sodium.beta.-phenylpyruvate and 100mL solvent anhydrous methanol, in temperature
20 h are reacted under conditions of being 45 ~ 65 DEG C, cooling, filtering controls solvent volatilization crystallization under conditions of 20 ~ 35 DEG C, obtains colourless
Transparent crystal, as 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex.Yield：73.9%.Fusing point：103~105
℃(dec)。
Elemental analysis (C62H60N4O8Sn2)：Calculated value：C 60.71, H 4.93, N 4.57；Measured value：C 60.74, H
4.99, N 4.59.
FT-IR (KBr, ν/cm-1): 3080, 3059, 3024, 2930, 1630, 1614, 1597, 1391,
1338, 696, 590, 555, 455, 440。
1H NMR (400 MHz, DMSO-d 6) δ(ppm): 7.87 (d, J = 7.1 Hz, 2H), 7.51-7.41
(m, 3H), 7.21-7.13 (m, 3H), 6.96 (d, J = 6.8 Hz, 2H), 6.78 (s, 6H), 6.69(m,
4H), 4.04 (s, 1H), 3.47 (s, 3H), 3.17 (s, 2H,), 2.88-2.81 (m, 4H)。
13C NMR (100 MHz, DMSO-d 6) δ(ppm): 172.75, 164.04, 151.85, 138.30,
135.97, 134.47, 130.72, 128.86, 127.90, 127.80, 127.76, 127.68, 127.10,
125.59, 123.79, 48.38, 37.04, 31.33。
119Sn NMR (187 MHz, DMSO-d 6) δ(ppm): -453.90。
Crystallographic data：Anorthic system, space group P-1, a=0.95601 (4) nm, b=1.22653 (5) nm, c=
1.26730 (5) nm, α=78.19 °, β=71.78 °, γ=86.0410 (10) °, Z=2, V=1.38155 (10) nm3,
Dc= 1.474 Mg·m-3, m (MoK α)=0.963 mm-1, F (000)=624.
Embodiment 5：
The preparation of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex：
In the 250mL three-necked flask for having nitrogen protection be added 1.860g (5.0mmol) TriphenylphosphineoxComplex,
0.707g (5.2mmol) benzoyl hydrazine, 1.042g (5.6mmol) Sodium.beta.-phenylpyruvate and 150mL solvent anhydrous methanol, in temperature
22 h are reacted under conditions of being 45 ~ 65 DEG C, cooling, filtering controls solvent volatilization crystallization under conditions of 20 ~ 35 DEG C, obtains colourless
Transparent crystal, as 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex.Yield：73.2%.Fusing point：103~105
℃(dec)。
Elemental analysis (C62H60N4O8Sn2)：Calculated value：C 60.71, H 4.93, N 4.57；Measured value：C 60.74, H
4.99, N 4.59.
FT-IR (KBr, ν/cm-1): 3080, 3059, 3024, 2930, 1630, 1614, 1597, 1391,
1338, 696, 590, 555, 455, 440。
1H NMR (400 MHz, DMSO-d 6) δ(ppm): 7.87 (d, J = 7.1 Hz, 2H), 7.51-7.41
(m, 3H), 7.21-7.13 (m, 3H), 6.96 (d, J = 6.8 Hz, 2H), 6.78 (s, 6H), 6.69(m,
4H), 4.04 (s, 1H), 3.47 (s, 3H), 3.17 (s, 2H,), 2.88-2.81 (m, 4H)。
13C NMR (100 MHz, DMSO-d 6) δ(ppm): 172.75, 164.04, 151.85, 138.30,
135.97, 134.47, 130.72, 128.86, 127.90, 127.80, 127.76, 127.68, 127.10,
125.59, 123.79, 48.38, 37.04, 31.33。
119Sn NMR (187 MHz, DMSO-d 6) δ(ppm): -453.90。
Crystallographic data：Anorthic system, space group P-1, a=0.95601 (4) nm, b=1.22653 (5) nm, c=
1.26730 (5) nm, α=78.19 °, β=71.78 °, γ=86.0410 (10) °, Z=2, V=1.38155 (10) nm3,
Dc= 1.474 Mg·m-3, m (MoK α)=0.963 mm-1, F (000)=624.
Embodiment 6：
The preparation of 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex：
In the 250mL three-necked flask for having nitrogen protection be added 3.720g (10.0mmol) TriphenylphosphineoxComplex,
1.387g (10.2mmol) benzoyl hydrazine, 1.972g (10.6mmol) Sodium.beta.-phenylpyruvate and 150mL solvent anhydrous methanol, in temperature
Degree reacts 24 h under conditions of being 45 ~ 65 DEG C, cooling, filtering, and solvent volatilization crystallization is controlled under conditions of 20 ~ 35 DEG C, obtains nothing
Color transparent crystal, as 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex.Yield：71.7%.Fusing point：103~
105℃(dec)。
Elemental analysis (C62H60N4O8Sn2)：Calculated value：C 60.71, H 4.93, N 4.57；Measured value：C 60.74, H
4.99, N 4.59.
FT-IR (KBr, ν/cm-1): 3080, 3059, 3024, 2930, 1630, 1614, 1597, 1391,
1338, 696, 590, 555, 455, 440。
1H NMR (400 MHz, DMSO-d 6) δ(ppm): 7.87 (d, J = 7.1 Hz, 2H), 7.51-7.41
(m, 3H), 7.21-7.13 (m, 3H), 6.96 (d, J = 6.8 Hz, 2H), 6.78 (s, 6H), 6.69(m,
4H), 4.04 (s, 1H), 3.47 (s, 3H), 3.17 (s, 2H,), 2.88-2.81 (m, 4H)。
13C NMR (100 MHz, DMSO-d 6) δ(ppm): 172.75, 164.04, 151.85, 138.30,
135.97, 134.47, 130.72, 128.86, 127.90, 127.80, 127.76, 127.68, 127.10,
125.59, 123.79, 48.38, 37.04, 31.33。
119Sn NMR (187 MHz, DMSO-d 6) δ(ppm): -453.90。
Crystallographic data：Anorthic system, space group P-1, a=0.95601 (4) nm, b=1.22653 (5) nm, c=
1.26730 (5) nm, α=78.19 °, β=71.78 °, γ=86.0410 (10) °, Z=2, V=1.38155 (10) nm3,
Dc= 1.474 Mg·m-3, m (MoK α)=0.963 mm-1, F (000)=624.
Test example：
2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex of the invention, Anticancer Activity in vitro measurement are
It is realized by MTT experiment method.
MTT analytic approach：
3- (4,5-Dimethylthiazol-2-yl) -2,5-diphenyltetrazolium is restored with metabolism
Based on bromide.Succinate dehydrogenase in living cells mitochondria can make exogenous MTT be reduced to the bluish violet of water-insoluble
Crystallize first a ceremonial jade-ladle, used in libation（Formazan）And be deposited in cell, and dead cell is without this function.Dimethyl sulfoxide（DMSO）Cell can be dissolved
In first a ceremonial jade-ladle, used in libation, with microplate reader measurement characteristic wavelength optical density, can reflect living cells quantity indirectly.
2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin the complex pair of the preparation of embodiment 1 is measured using mtt assay
Human colon cancer cell（Colo205）, human liver cancer cell（HepG2）, human breast cancer cell（MCF7）, human cervical carcinoma cell
（Hela）And human lung carcinoma cell（NCI-H460）Inhibitory activity.
Cell strain and cultivating system：Colo205, HepG2, MCF7, Hela and NCI-H460 cell strain are derived from American tissue
Incubator（ATCC）.With the RPMI 1640 for containing 10% fetal calf serum（GIBICO company）Culture medium, 5%（Volume fraction）CO2、
In vitro culture is carried out in 37 DEG C of saturated humidity incubators.
Test process：Medical fluid will be tested（0.1ng/mL~10ug/mL）It is added separately to according to the concentration gradient of concentration each
Kong Zhong, each concentration set 6 parallel holes.Experiment is divided into drug study group（It is separately added into the test medicine of various concentration）, control group
（Only add culture solution and cell, test medicine is not added）And blank group（Only plus medicine is cultivated, cell and test medicine is not added）.After dosing
Orifice plate is placed in 37 DEG C, 5%CO272h is cultivated in incubator.The activity of control drug is measured according to the method for test sample.It is cultivating
In orifice plate after 72h, every hole adds MTT 40uL（4mg/mL is made into D-Hanks buffer）.After 37 DEG C of placement 4h, remove
Supernatant liquor.Every hole adds 150uL DMSO, vibrates 5min, makes Formazan crystallization dissolution.Finally, being existed using automatic microplate reader
The optical density in each hole is detected at 570nm wavelength.
Data processing：Data processing uses 5.0 program of Graph Pad Prism version, complex IC50Pass through journey
Nonlinear regression model (NLRM) in sequence with S-shaped dose response is fitted to obtain.
With MTT analytic approach to human colon cancer cell（Colo205）, human liver cancer cell（HepG2）, human breast cancer cell
（MCF7）, human cervical carcinoma cell（Hela）And human lung carcinoma cell（NCI-H460）Cell strain is analyzed, its IC is measured50Value,
The results are shown in Table 1, and conclusion is：From the data in the table, with 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone dibenzyl of the invention
Tin complex is used as anticancer drug, to human colon cancer cell（Colo205）, human liver cancer cell（HepG2）, human breast cancer cell
（MCF7）, human cervical carcinoma cell（Hela）And human lung carcinoma cell（NCI-H460）With certain drug effect, anticarcinogen can be used as
The candidate compound of object.
1 2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin complex anticancer drug external activity test data of table.
2- carbonyl -3- phenylpropionic acid benzoyl hydrazone Dibenzyltin the complex of remaining embodiment preparation ties people with mtt assay
Colon-cancer cell（Colo205）, human liver cancer cell（HepG2）, human breast cancer cell（MCF7）, human cervical carcinoma cell（Hela）With
Human lung carcinoma cell（NCI-H460）The same test example of anticancer activity test method, test result and table 1 are essentially identical.
Claims (6)
1. a kind of benzoyl hydrazone Dibenzyltin complex is the complex of following structure formula (I)：
(I)
Wherein Ph is phenyl, and R is benzyl, and the complex (I) is crystal structure, and crystallographic data is as follows：Anorthic system,
Space group P-1, a=0.95601 (4) nm, b=1.22653 (5) nm, c=1.26730 (5) nm, α=78.19 °, β
=71.78 °, γ=86.0410 (10) °, Z=2, V=1.38155 (10) nm3, the Mgm of Dc=1.474-3, m (MoK α)=
0.963 mm-1, F (000)=624；Tin atom is seven coordination distortion pentagonal bipyramid configurations in molecule；The complex (I)
Ir data：FT-IR (KBr, ν/cm-1): 3080, 3059, 3024, 2930, 1630, 1614, 1597,
1391, 1338, 696, 590, 555, 455, 440；Its nuclear-magnetism modal data：1H NMR (400 MHz, DMSO-d 6) δ
(ppm): 7.87 (d, J = 7.1 Hz, 2H), 7.51-7.41 (m, 3H), 7.21-7.13 (m, 3H), 6.96
(d, J = 6.8 Hz, 2H), 6.78 (s, 6H), 6.69(m, 4H), 4.04 (s, 1H), 3.47 (s, 3H),
3.17 (s, 2H,), 2.88-2.81 (m, 4H)；13C NMR (100 MHz, DMSO-d 6) δ(ppm): 172.75,
164.04, 151.85, 138.30, 135.97, 134.47, 130.72, 128.86, 127.90, 127.80,
127.76, 127.68, 127.10, 125.59, 123.79, 48.38, 37.04, 31.33；119Sn NMR (187
MHz, DMSO-d 6) δ(ppm): -453.90；The complex (I) can be stabilized at 103 DEG C or less.
2. the preparation method of benzoyl hydrazone Dibenzyltin complex described in claim 1, it is characterized in that there is nitrogen protection
TriphenylphosphineoxComplex, benzoyl hydrazine, Sodium.beta.-phenylpyruvate and solvent anhydrous methanol are added in reaction vessel, is 45 ~ 65 in temperature
5 ~ 24 h are reacted under conditions of DEG C, cooling, filtering controls solvent volatilization crystallization under conditions of 20 ~ 35 DEG C, obtains colorless and transparent crystalline substance
Body, as benzoyl hydrazone Dibenzyltin complex.
3. preparation method as claimed in claim 2, which is characterized in that the TriphenylphosphineoxComplex, benzoyl hydrazine, propiophenone
The mass ratio of the material of sour sodium three is 1:(1~1.05):(1.05~1.15).
4. preparation method as claimed in claim 2, which is characterized in that the solvent anhydrous methanol dosage is every mM of dibenzyl
Base stannous chloride adds 15 ~ 35 milliliters.
5. benzoyl hydrazone Dibenzyltin complex described in claim 1 is preparing the application in anticancer drug.
6. application described in claim 5, wherein the cancer cell is human liver cancer cell, human cervical carcinoma cell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610254542.0A CN105777799B (en) | 2016-04-22 | 2016-04-22 | A kind of benzoyl hydrazone Dibenzyltin complex and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610254542.0A CN105777799B (en) | 2016-04-22 | 2016-04-22 | A kind of benzoyl hydrazone Dibenzyltin complex and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105777799A CN105777799A (en) | 2016-07-20 |
| CN105777799B true CN105777799B (en) | 2018-11-27 |
Family
ID=56397210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610254542.0A Active CN105777799B (en) | 2016-04-22 | 2016-04-22 | A kind of benzoyl hydrazone Dibenzyltin complex and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105777799B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106279250B (en) * | 2016-08-13 | 2018-11-27 | 衡阳师范学院 | A kind of stannous phenide complex and its preparation method and application |
| CN106279261B (en) * | 2016-08-22 | 2018-09-14 | 衡阳师范学院 | A kind of di-n-butyl tin complex and its preparation method and application |
| CN106366114A (en) * | 2016-08-22 | 2017-02-01 | 衡阳师范学院 | 2-Oxo-3-phenylpropionic acid p-methylbenzoyl hydrazone dibenzyltin complex, and preparation method and application thereof |
| CN106220670B (en) * | 2016-08-23 | 2018-09-14 | 衡阳师范学院 | Two pairs of methylbenzyl tin complexs of one kind and its preparation method and application |
| CN106366117A (en) * | 2016-08-24 | 2017-02-01 | 衡阳师范学院 | 2-carbonyl-3-phenylpropionic-p-tert-butyl benzoyl hydrazone dibenzyl tin complex, and preparation method and application thereof |
| CN106220674B (en) * | 2016-08-26 | 2018-09-07 | 衡阳师范学院 | A kind of Dibenzyltin complex and its preparation method and application |
| CN106432324A (en) * | 2016-08-29 | 2017-02-22 | 衡阳师范学院 | 2-carbonyl-3-phenylpropionic acid p-methoxybenzoyl hydrazone dibenzyl stannic complex as well as preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105198921A (en) * | 2015-11-11 | 2015-12-30 | 衡阳师范学院 | 2-carbonyl-2-phenylacetic acid salicyloyl hydrazone dibutyltin complex as well as preparation method and application of 2-carbonyl-2-phenylacetic acid salicyloyl hydrazone dibutyltin complex |
| CN105237564A (en) * | 2015-11-11 | 2016-01-13 | 衡阳师范学院 | 2-carbonyl-3-phenylpropionic acid salicylhydrazone bis(p-methylbenzyl)tin complex and preparation method and application thereof |
| CN105384770A (en) * | 2015-11-11 | 2016-03-09 | 衡阳师范学院 | 2-oxo-propionic acid salicyloyl hydrazone and di(p-methylbenzyl)tin complex as well as preparation method and application of 2-oxo-propionic acid salicyloyl hydrazone and di(p-methylbenzyl)tin complex |
-
2016
- 2016-04-22 CN CN201610254542.0A patent/CN105777799B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105198921A (en) * | 2015-11-11 | 2015-12-30 | 衡阳师范学院 | 2-carbonyl-2-phenylacetic acid salicyloyl hydrazone dibutyltin complex as well as preparation method and application of 2-carbonyl-2-phenylacetic acid salicyloyl hydrazone dibutyltin complex |
| CN105237564A (en) * | 2015-11-11 | 2016-01-13 | 衡阳师范学院 | 2-carbonyl-3-phenylpropionic acid salicylhydrazone bis(p-methylbenzyl)tin complex and preparation method and application thereof |
| CN105384770A (en) * | 2015-11-11 | 2016-03-09 | 衡阳师范学院 | 2-oxo-propionic acid salicyloyl hydrazone and di(p-methylbenzyl)tin complex as well as preparation method and application of 2-oxo-propionic acid salicyloyl hydrazone and di(p-methylbenzyl)tin complex |
Non-Patent Citations (1)
| Title |
|---|
| 基于水杨酰腙配体的二丁基锡配合物的合成、晶体结构、热稳定性及与DNA相互作用;郑建华等;《应用化学》;CNKI;20150531;第32卷(第5期);第562-569页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105777799A (en) | 2016-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105198921B (en) | A kind of 2- carbonyl -2- phenylacetic acid salicyloyl hydrazone dibutyl tin complex and its preparation method and application | |
| CN105777799B (en) | A kind of benzoyl hydrazone Dibenzyltin complex and its preparation method and application | |
| CN105237564B (en) | A kind of phenylpropionic acid salicyloyl hydrazone two of 2 carbonyl 3 is to methyl-benzyl tin complex and its preparation method and application | |
| CN105237563B (en) | A kind of 2 carbonyl propionic acid para hydroxybenzene formyl hydrazone two (2,4 dichloro benzyl) tin complexs and its preparation method and application | |
| CN105384770B (en) | A kind of 2 carbonyl propionic acid salicyloyl hydrazones two are to methyl-benzyl tin complex and its preparation method and application | |
| CN105601663B (en) | A kind of phenylacetic acid salicyloyl hydrazone stannous phenide complex of 2 carbonyl 2 and its preparation method and application | |
| CN105777798A (en) | 2-carbonyl-2-phenylacetic acid para hydroxybenzene formyl hydrazone dibutyl tin complex as well as preparation method and application thereof | |
| CN105541898B (en) | A kind of phenylpropionic acid benzoyl hydrazone two of 2 carbonyl 3 is to methyl-benzyl tin complex and its preparation method and application | |
| CN105237562A (en) | 2-oxo propionic acid salicyloyl hydrazone tin diphenyl complex and preparation method and application thereof | |
| CN105348318A (en) | 2-carbonyl butyric acid benzoyl hydrazone dibenzyl tin complex, preparation method therefor and applications | |
| CN105732698A (en) | 2-carbonyl-3-phenylpropionic acid salicyloyl hydrazone bi(2,4-dichloro benzyl) tin complex and preparation method and application thereof | |
| CN105753896A (en) | 2-carbonyl-3-phenylpropionic acid p-hydroxyphenylcarbonylhydrazone dibenzyl tin complex as well as preparation method and application thereof | |
| CN105693762A (en) | 2-carbonyl-2-phenylacetic acid benzoylhydrazone di-n-butyltin tin complex and preparation method and application thereof | |
| CN105859768A (en) | 2-carbonyl-3-phenylpropionic acid salicylhydrazone dibenzyltin complex and preparation method and application thereof | |
| CN105693763B (en) | A kind of organotin complex of the ligand containing acylhydrazone and its preparation method and application | |
| CN105693761A (en) | 2-carbonyl-3-phenylpropionic acid salicylacylhydrazone diphenyl tin complex as well as preparation method and application thereof | |
| CN105884818B (en) | 2-carbonyl-3-phenylpropionic acid benzoyl hydrazone diphenyltin complex and preparation method and application thereof | |
| CN105399764B (en) | A kind of 2 carbonyl propionic acid benzoyl hydrazone Dibenzyltin complexs and its preparation method and application | |
| CN106336427B (en) | A kind of 2- carbonyl -2- phenylacetic acid p-nitrophenyl formyl hydrazone two (2,4- dichloro benzyl) tin complex and its preparation method and application | |
| CN105399765B (en) | A kind of 2 carbonyl propionic acid benzoyl hydrazone tribenzyltin complexs and its preparation method and application | |
| CN106380480B (en) | A kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide complex and its preparation method and application | |
| CN106317105B (en) | A kind of 2- carbonyl -2- phenylacetic acid p-nitrophenyl formyl hydrazone di-n-butyl tin complex and its preparation method and application | |
| CN106366120B (en) | A kind of ALPHA-ketobutyric acid is to methoxybenzoyl hydrazone stannous phenide complex and its preparation method and application | |
| CN106220675B (en) | A kind of stannous phenide complex of the ligand containing acylhydrazone and its preparation method and application | |
| CN105601664B (en) | A kind of 2 carbonyl propionic acid salicyloyl hydrazone cyclohexyl tin complexs and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |